13G Filing: Jafco Sv4 Investment Limited Partnership and Miragen Therapeutics Inc. (NASDAQ:MGEN)

Page 2 of 8 – SEC Filing

13G

CUSIP No. 60463E103 Page 2 of 8
1. NAMES OF REPORTING PERSONS

JAFCO SV4 Investment Limited Partnership (“JAFCO SV4”)
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions)
(a)    ¨
(b)    x
3. SEC USE ONLY
 
4. CITIZENSHIP OR PLACE OF ORGANIZATION
 
Japan
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER
 
1,160,406 shares, except that
JAFCO Co., Ltd., the general partner of JAFCO SV4, may be deemed to have sole power to vote these shares.
6. SHARED VOTING POWER
 
See response to row 5.
7. SOLE DISPOSITIVE POWER
 
1,160,406 shares, except that
JAFCO Co., Ltd., the general partner of JAFCO SV4, may be deemed to have sole power to dispose of these shares.
8. SHARED DISPOSITIVE POWER
 
See response to row 7.
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

1,160,406 shares
10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
(see instructions)    ¨
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

5.4%
12. TYPE OF REPORTING PERSON (see instructions)

PN
Follow Viridian Therapeutics Inc. (NASDAQ:VRDN)